Glycemic control and heart disease.
The leading cause of death among patients with diabetes is cardiovascular disease with approximately 80% of all deaths being attributed to coronary heart disease. Acute myocardial infarctions (AMIs) in patients with diabetes are associated with an increased rate of reinfarction than those without diabetes. Following AMI, patients with diabetes are more likely to develop severe heart failure. The Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) clinical trial examined the relationship between intensive insulin and conventional therapy following AMI. Results of the DIGAMI study clearly identify the need for tight glucose control following AMI in improving clinical outcomes and mortality.
Colwell
L
L
Cardiovascular Nurse Clinician, Alexian Brothers Hospital, Elk Grove Village, Illinois, USA.
Quinn
L
L
D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D002423:Cause of Death; D003422:Critical Care / Q000379:methods; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000453:epidemiology / Q000628:therapy*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006331:Heart Diseases / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007328:Insulin / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications / Q000628:therapy; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin